SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Howe who wrote (1297)10/14/1998 1:50:00 PM
From: BMcV  Read Replies (1) of 10280
 
David,

I agree with your thinking, but wonder if this might not be getting personal between Lilly and Sepracor. Sepracor's strategy has always been controversial (see "Drug pirates make good") and while some companies can admit they blew it (by missing the opportunities Sepracor saw to patent method-of-use for single isomers and active metabolites), and put that behind them, and make the deal that makes sense (J&J), others might rather die than come around. As you say, though, sooner or later Lilly may have to sign on, but then it will be at a higher cost, if we can prove in the meantime that r-fluo has real advantages.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News